DAVITA INC shareholders Q3 2023

DAVITA INC's ticker is DVA and the CUSIP is 23918K108. A total of 499 filers reported holding DAVITA INC in Q3 2023. The put-call ratio across all filers is 2.89 and the average weighting 0.1%.

DAVITA INC shareholders Q3 2023
Name	Shares	Value	Weighting ↓
John W. Brooker & Co., CPAs	3,266	$308,735	0.20%
Virtus Investment Advisers, Inc.	2,949	$278,769	0.19%
Cinctive Capital Management LP	39,408	$3,725,238	0.18%
Woodline Partners LP	164,881	$15,586,201	0.18%
Gotham Asset Management, LLC	91,195	$8,620,663	0.18%
Bayesian Capital Management, LP	16,089	$1,520,893	0.17%
ROMANO BROTHERS AND COMPANY	15,725	$1,486,484	0.17%
SHERBROOKE PARK ADVISERS LLC	5,608	$530,124	0.17%
EQUITABLE TRUST CO	21,293	$2,012,827	0.17%
CONTRAVISORY INVESTMENT MANAGEMENT, INC.	5,950	$562,454	0.16%
Versor Investments LP	8,241	$779,022	0.16%
Nilsine Partners, LLC	10,771	$1,018,183	0.15%
Pine Valley Investments Ltd Liability Co	17,273	$1,632,817	0.15%
MARSHALL WACE, LLP	736,010	$69,575,025	0.14%
Quantbot Technologies LP	21,071	$1,991,842	0.13%
Railway Pension Investments Ltd	131,156	$12,398,177	0.13%
Teza Capital Management LLC	14,015	$1,324,838	0.12%
Dynamic Technology Lab Private Ltd	12,601	$1,191	0.12%
Leucadia National	138,700	$13,111,311	0.12%
INTECH INVESTMENT MANAGEMENT LLC	84,555	$7,992,985	0.12%

About DAVITA INC

DaVita Inc. is a leading provider of kidney care services in the United States. The company operates more than 2,700 dialysis clinics across the country, serving approximately 203,000 patients. DaVita's mission is to improve the quality of life for those living with kidney disease, and the company is committed to providing high-quality, compassionate care to its patients.

DaVita's success can be attributed to its focus on patient-centered care. The company's care teams work closely with patients to develop personalized treatment plans that meet their unique needs. DaVita also invests heavily in technology and innovation to improve patient outcomes and enhance the overall patient experience.

In addition to its core kidney care services, DaVita also operates a number of strategic business units, including DaVita Kidney Care, DaVita Medical Group, and DaVita International. These units allow the company to diversify its revenue streams and expand its reach into new markets.

Despite its success, DaVita faces a number of challenges in the highly competitive healthcare industry. The company must navigate complex regulatory environments, manage rising healthcare costs, and adapt to changing patient needs and preferences.

Overall, DaVita is a strong player in the kidney care market, with a proven track record of delivering high-quality care to its patients. As the healthcare industry continues to evolve, DaVita will need to remain agile and innovative to stay ahead of the curve.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists DAVITA INC's shareholders in Q3 2023. To view DAVITA INC's shareholder history, click here.